{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:57:18Z","timestamp":1767772638445,"version":"3.41.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jns.2017.09.006","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T21:40:57Z","timestamp":1504734057000},"page":"285-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Microglial\/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges"],"prefix":"10.1016","volume":"381","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan R.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.09.006_bb0005","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1172\/JCI58644","article-title":"Innate immunity in the central nervous system","volume":"122","author":"Ransohoff","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2017.09.006_bb0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2174\/092986707780597961","article-title":"Microglial activation and its implications in the brain diseases","volume":"14","author":"Dheen","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jns.2017.09.006_bb0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","article-title":"Astrocytes are active players in cerebral innate immunity","volume":"28","author":"Farina","year":"2007","journal-title":"Trends Immunol."},{"issue":"Pt1","key":"10.1016\/j.jns.2017.09.006_bb0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.09.006_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.12.014","article-title":"Key role of CXCL13\/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS","volume":"243","author":"Pranzatelli","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-2094-10-10","article-title":"BAFF\/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy","volume":"10","author":"Pranzatelli","year":"2013","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.jns.2017.09.006_bb0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/cei.12065","article-title":"Expression of CXCR3 and its ligands CXCL9, -10, -11 in pediatric OMS","volume":"172","author":"Pranzatelli","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archneur.1979.00500370081022","article-title":"Neuropathological findings in a patient with neuroblastoma and myoclonic encephalopathy","volume":"36","author":"Ziter","year":"1979","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2017.09.006_bb0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF00344353","article-title":"Opsoclonus-myoclonus syndrome: correlation of radiographic and pathologic observations","volume":"31","author":"Tuchman","year":"1989","journal-title":"Neuroradiology"},{"key":"10.1016\/j.jns.2017.09.006_bb0050","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mpo.2950210916","article-title":"Adrenocorticotropic hormone-secreting ganglioneuroblastoma associated with opsomyoclonic encephalopathy: a case report with immunohistochemical study","volume":"21","author":"Clerico","year":"1993","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.jns.2017.09.006_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0165-5728(02)00353-3","article-title":"The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b","volume":"133","author":"Brettschneider","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jneuroim.2006.09.002","article-title":"Increased serum levels of soluble CD14 indicate stable multiple sclerosis","volume":"181","author":"Lutterotti","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0065","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/315357","article-title":"Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease","volume":"181","author":"Lin","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jns.2017.09.006_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0165-5728(99)00141-1","article-title":"Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral infections","volume":"101","author":"Nockher","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-2094-7-34","article-title":"In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases","volume":"7","author":"Bonneh-Barkay","year":"2010","journal-title":"J. Neuroinflammation"},{"issue":"14","key":"10.1016\/j.jns.2017.09.006_bb0080","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1177\/1352458515574148","article-title":"Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis","volume":"21","author":"Modvig","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.jns.2017.09.006_bb0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/1352458511433063","article-title":"Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis","volume":"18","author":"Cant\u00f3","year":"2012","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.jns.2017.09.006_bb0090","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/1352458514561906","article-title":"Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis","volume":"21","author":"Hinsinger","year":"2015","journal-title":"Mult. Scler."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.09.006_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2014.02.004","article-title":"CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment","volume":"269","author":"Malmestr\u00f6m","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365513.2011.626868","article-title":"Soluble CD163","volume":"72","author":"M\u00f8ller","year":"2012","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"7","key":"10.1016\/j.jns.2017.09.006_bb0105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.braindev.2012.10.005","article-title":"Serum soluble CD163 levels in patients with influenza associated encephalopathy","volume":"35","author":"Hasegawa","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.jns.2017.09.006_bb0110","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1007\/s00125-012-2533-1","article-title":"Soluble CD163: a biomarker linking macrophages and insulin resistance","volume":"55","author":"Parkner","year":"2012","journal-title":"Diabetalogia"},{"key":"10.1016\/j.jns.2017.09.006_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1684\/ejd.2012.1756","article-title":"CD163 expression is involved in the skin and sera of patients with systemic lupus erythematosus","volume":"22","author":"Nakayama","year":"2012","journal-title":"Eur. J. Dermatol."},{"issue":"3","key":"10.1016\/j.jns.2017.09.006_bb0120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1515\/hsz-2015-0269","article-title":"Role of chitinase-like proteins in cancer","volume":"397","author":"Kzhyshkowska","year":"2016","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jns.2017.09.006_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijbiomac.2017.01.042","article-title":"Chitin and chitinase: role in pathogenicity, allergenicity and health","volume":"97","author":"Patel","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jns.2017.09.006_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12879-016-1510-6","article-title":"Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study","volume":"16","author":"Jespersen","year":"2016","journal-title":"BMN Infect. Dis."},{"issue":"3","key":"10.1016\/j.jns.2017.09.006_bb0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1753425910369271","article-title":"Review: soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbation or resolving inflammation","volume":"16","author":"Litvack","year":"2010","journal-title":"Innate Immun."},{"issue":"1","key":"10.1016\/j.jns.2017.09.006_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2012-120787","article-title":"Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia","volume":"33","author":"Olsson","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.jns.2017.09.006_bb0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/jir.2012.0132","article-title":"Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay","volume":"33","author":"Pranzatelli","year":"2013","journal-title":"J. Interfer. Cyto. Res."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.09.006_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2013.11.004","article-title":"CSF neurofilament light chain is increased in OMS, decreasing with immunotherapy, and other pediatric neuroinflammatory disorders","volume":"266","author":"Pranzatelli","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.09.006_bb0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2016.08.004","article-title":"Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis","volume":"299","author":"Ma\u00f1\u00e9-Martinez","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jns.2017.09.006_bb0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/WCO.0000000000000336","article-title":"Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response","volume":"29","author":"Comabella","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2017.09.006_bb0170","doi-asserted-by":"crossref","first-page":"e0163479","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jns.2017.09.006_bb0175","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1183\/09031936.00034409","article-title":"YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E","volume":"35","author":"Tang","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.jns.2017.09.006_bb0180","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1189\/jlb.3VMR0415-142R","article-title":"YKL-40\/CHI3L1 drives inflammation on the road of tumor progression","volume":"98","author":"Libreros","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jns.2017.09.006_bb0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0b013e318256f3bc","article-title":"Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV activation","volume":"60","author":"Kamat","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jns.2017.09.006_bb0190","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1212\/WNL.0b013e3181d5dc3b","article-title":"CSF glial markers correlate with survival in amyotrophic lateral sclerosis","volume":"74","author":"S\u00fcssmuth","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2017.09.006_bb0195","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.4049\/jimmunol.162.8.4762","article-title":"The origin and function of soluble CD14 in experimental bacterial meningitis","volume":"162","author":"Cauwels","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2017.09.006_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jneuroim.2007.04.016","article-title":"Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis","volume":"187","author":"Fabriek","year":"2007","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jns.2017.09.006_bb0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00296-012-2459-4","article-title":"Soluble CD163 serum levels are elevated and correlated with IL-2 and CXCL10 in patients with long-standing rheumatoid arthritis","volume":"33","author":"Jude","year":"2013","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.jns.2017.09.006_bb0210","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jns.2017.09.006_bb0215","doi-asserted-by":"crossref","first-page":"e98588","DOI":"10.1371\/journal.pone.0098588","article-title":"Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis","volume":"9","author":"Stilund","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17342879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17342879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:17:17Z","timestamp":1750868237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17342879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":43,"alternative-id":["S0022510X17342879"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.09.006","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microglial\/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}